{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sutro Biopharma, Inc.
Sutro Biopharma Hits New 52-Week High of $25.68, Soars 556.88%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a significant stock increase over the past year. The company, with a market capitalization of USD 302 million, showcases impressive financial metrics despite being loss-making and not offering dividends.
Sutro Biopharma Hits New 52-Week High at $22.76, Up 484%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a significant stock increase over the past year. The company, with a market capitalization of USD 302 million, showcases impressive financial metrics despite being unprofitable and lacking a dividend. Its recent turnaround highlights the dynamic biotechnology market.
Sutro Biopharma Hits New 52-Week High of $21.40, Soars 453%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock price over the past year. With a market capitalization of USD 302 million, the company demonstrates strong equity management despite being loss-making and lacking a dividend. Its financial structure features a notable debt-to-equity ratio.
Sutro Biopharma Hits New 52-Week High of $20.93, Up 431.69%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a remarkable 431.69% increase over the past year. With a market capitalization of USD 302 million, the company has shown strong financial metrics despite being loss-making, and it continues to evolve within the pharmaceuticals and biotechnology sector.
Sutro Biopharma Hits New 52-Week High of $20.48, Up 431.69%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a significant stock increase over the past year. The company, with a market capitalization of USD 302 million, showcases impressive financial metrics despite being loss-making and lacking a dividend. Its growth highlights its evolving presence in the biotechnology sector.
Sutro Biopharma Hits New 52-Week High at $20.47, Soars 430%
Sutro Biopharma, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a significant stock increase over the past year. The company, with a market capitalization of USD 302 million, has shown impressive financial metrics despite being loss-making and lacking a dividend.
Is Sutro Biopharma, Inc. technically bullish or bearish?
As of September 12, 2025, Sutro Biopharma's technical trend is neutral with mixed signals, showing a year-to-date return of -50.93% compared to the S&P 500's 12.22%.
Is Sutro Biopharma, Inc. overvalued or undervalued?
As of March 18, 2021, Sutro Biopharma, Inc. is considered overvalued and risky due to significant financial distress, reflected in poor valuation metrics and a year-to-date stock decline of 50.93%, compared to the S&P 500's positive return of 12.22%.
Is Sutro Biopharma, Inc. overvalued or undervalued?
As of March 18, 2021, Sutro Biopharma, Inc. is considered overvalued and in financial distress, with poor valuation metrics compared to peers and a year-to-date stock return of -56.59%.
Is Sutro Biopharma, Inc. technically bullish or bearish?
As of June 13, 2025, Sutro Biopharma, Inc. is in a bearish trend with moderate strength, indicated by bearish signals from moving averages, MACD, and Bollinger Bands, despite a mildly bullish weekly KST, and has underperformed the S&P 500.
Who are in the management team of Sutro Biopharma, Inc.?
As of March 2022, the management team of Sutro Biopharma, Inc. includes Chairman Connie Matsui, CEO William Newell, and Directors James Panek, Daniel Petree, Jon Wigginton, Michael Dybbs, and John Freund. They oversee the company's strategic direction and operations.
What does Sutro Biopharma, Inc. do?
Sutro Biopharma, Inc. is a clinical stage company focused on developing protein therapeutics for cancer and autoimmune disorders. As of March 2025, it reported net sales of $17 million and a net loss of $76 million, with a market cap of $66.73 million.
How big is Sutro Biopharma, Inc.?
As of Jun 18, Sutro Biopharma, Inc. has a market capitalization of 66.73 million, with net sales of 66.44 million and a net profit of -245.22 million over the last four quarters. The company's shareholder's funds are 44.60 million, and total assets are 387.21 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
